Sabork
“Purifying the earth, one feet pic at a time”
- Joined
- Dec 24, 2025
- Posts
- 1,624
- Reputation
- 1,346
HEIGHTMAXXING 101
made by @Sabork
TABLE OF CONTENTS
INTRODUCTION
Growth prediction, Tanner stages and Bone age.
This is a CDC chart published in the 2000s based on United States population data. The chart serves as a reference to check if the growth of a child or teenager is on track. By comparing measurements over time, shifts in percentiles might indicate potential health issues. This system helps keep track of an individual’s growth simply by looking at their age and comparing it to the average height percentile for that age group.
Tanner stages are unreliable and bone age aligns with real age for most people
It is very important to understand this since many people still rely on weak or misleading indicators such as facial hair, pubic hair, or other visible signs to assume that growth has stopped. Puberty and skeletal maturation are related but not perfectly synchronized processes. Hormonal changes and secondary sexual characteristics develop at different rates and are strongly influenced by genetics and ethnicity.
For example, a person might appear to be in mid puberty, around Tanner stage three or four, but still have open and responsive growth plates. This shows that external puberty signs are not a reliable way to determine maturity or predict how much growth remains. Even trained physicians have only around 53 to 59 percent accuracy when estimating Tanner stages, with particularly poor accuracy at stage three. This means that up to 40 percent of classifications can be incorrect.
The genetic and ethnic diversity of modern populations in the United States and Europe makes Tanner staging even less reliable. Some people develop facial and pubic hair very early but still have open growth plates, while others may show these signs later when their plates are already closed. This wide variation means that external features give little real information about skeletal maturity.
The best and most objective way to assess growth potential is through bone age evaluation using imaging, preferably with a wrist or knee X ray. Bone age directly shows the condition of the growth plates and gives a more accurate picture of how far along someone is in their biological development. For most individuals, bone age is within about one year of their real age. This means that 95 percent of people have a bone age that closely matches their chronological age. In a typical classroom, you will notice that most students look close to their actual ages, with only a few appearing noticeably older or younger. Those few usually have bone age that is slightly ahead or behind their real age. This pattern shows how closely bone age reflects true physical development in most people.
TLDR: Tanner stages are unreliable because genetics and ethnicity affect how puberty appears physically, while skeletal growth follows its own timeline. A knee X ray remains the most accurate way to determine true bone age and ongoing growth potential.
HGH and Als (Biology, Protocols, Studies)
Rep me
Took me almost 4 days to make this
made by @Sabork
TABLE OF CONTENTS
Glossary
Introduction
Growth Chart Prediction, Tanner stage and Bone age
HGH and AIs (Biology, Protocols, Studies)
Introduction
Growth Chart Prediction, Tanner stage and Bone age
HGH and AIs (Biology, Protocols, Studies)
Aromatase Inhibitor (AI): Drug that blocks the enzyme converting testosterone to estrogen.
Used to delay growth-plate closure.
Bone Age: X-ray assessment of skeletal maturity (how “old” your bones are vs. chronological age).
Consolidation Phase: Period after lengthening where new bone hardens and strengthens (usually 2–4 months).
Distraction Osteogenesis: Process of slowly pulling cut bone apart so new bone forms in the gap.
Epiphyseal (Growth) Plates: Cartilage areas at the ends of long bones where lengthening occurs; they fuse (close) under estrogen influence, ending natural height growth.
Precice, STRYDE, Fitbone etc.: Telescopic rod implanted inside the bone; lengthened by magnetic remote. Preferred for cosmetics and lower infection risk.
GHRH / Somatostatin / Ghrelin: Key hormones regulating natural HGH pulses.
HGH (Human Growth Hormone / rhGH): 191-amino-acid hormone that drives bone, muscle, and tissue growth. Synthetic version used for height.
IGF-1: Main downstream mediator of HGH; produced mostly in the liver; directly stimulates cartilage growth in growth plates.
ISS (Idiopathic Short Stature): Short stature with no identifiable medical cause.
Latency Phase: 5–7 days after bone is cut before lengthening begins (allows initial healing).
SDS (Standard Deviation Score): How many standard deviations your height is from the average for your age/sex.
Staged Lengthening: One bone segment (or pair of limbs) at a time, with 6–12+ months healing between rounds.
Trenbolone (“Tren”): A potent 19nor anabolic steroid for muscle preservation (very potent, but also harsh side-effect profile).
Used to delay growth-plate closure.
Bone Age: X-ray assessment of skeletal maturity (how “old” your bones are vs. chronological age).
Consolidation Phase: Period after lengthening where new bone hardens and strengthens (usually 2–4 months).
Distraction Osteogenesis: Process of slowly pulling cut bone apart so new bone forms in the gap.
Epiphyseal (Growth) Plates: Cartilage areas at the ends of long bones where lengthening occurs; they fuse (close) under estrogen influence, ending natural height growth.
Precice, STRYDE, Fitbone etc.: Telescopic rod implanted inside the bone; lengthened by magnetic remote. Preferred for cosmetics and lower infection risk.
GHRH / Somatostatin / Ghrelin: Key hormones regulating natural HGH pulses.
HGH (Human Growth Hormone / rhGH): 191-amino-acid hormone that drives bone, muscle, and tissue growth. Synthetic version used for height.
IGF-1: Main downstream mediator of HGH; produced mostly in the liver; directly stimulates cartilage growth in growth plates.
ISS (Idiopathic Short Stature): Short stature with no identifiable medical cause.
Latency Phase: 5–7 days after bone is cut before lengthening begins (allows initial healing).
SDS (Standard Deviation Score): How many standard deviations your height is from the average for your age/sex.
Staged Lengthening: One bone segment (or pair of limbs) at a time, with 6–12+ months healing between rounds.
Trenbolone (“Tren”): A potent 19nor anabolic steroid for muscle preservation (very potent, but also harsh side-effect profile).
INTRODUCTION
.This guide outlines all established height optimization methods, from HGH and aromatase inhibitors
Growth prediction, Tanner stages and Bone age.
https://***********/attachments/image_2026-03-06_174018494-png.34746/
This is a CDC chart published in the 2000s based on United States population data. The chart serves as a reference to check if the growth of a child or teenager is on track. By comparing measurements over time, shifts in percentiles might indicate potential health issues. This system helps keep track of an individual’s growth simply by looking at their age and comparing it to the average height percentile for that age group.
Tanner stages are unreliable and bone age aligns with real age for most people
It is very important to understand this since many people still rely on weak or misleading indicators such as facial hair, pubic hair, or other visible signs to assume that growth has stopped. Puberty and skeletal maturation are related but not perfectly synchronized processes. Hormonal changes and secondary sexual characteristics develop at different rates and are strongly influenced by genetics and ethnicity.
For example, a person might appear to be in mid puberty, around Tanner stage three or four, but still have open and responsive growth plates. This shows that external puberty signs are not a reliable way to determine maturity or predict how much growth remains. Even trained physicians have only around 53 to 59 percent accuracy when estimating Tanner stages, with particularly poor accuracy at stage three. This means that up to 40 percent of classifications can be incorrect.
The genetic and ethnic diversity of modern populations in the United States and Europe makes Tanner staging even less reliable. Some people develop facial and pubic hair very early but still have open growth plates, while others may show these signs later when their plates are already closed. This wide variation means that external features give little real information about skeletal maturity.
The best and most objective way to assess growth potential is through bone age evaluation using imaging, preferably with a wrist or knee X ray. Bone age directly shows the condition of the growth plates and gives a more accurate picture of how far along someone is in their biological development. For most individuals, bone age is within about one year of their real age. This means that 95 percent of people have a bone age that closely matches their chronological age. In a typical classroom, you will notice that most students look close to their actual ages, with only a few appearing noticeably older or younger. Those few usually have bone age that is slightly ahead or behind their real age. This pattern shows how closely bone age reflects true physical development in most people.
TLDR: Tanner stages are unreliable because genetics and ethnicity affect how puberty appears physically, while skeletal growth follows its own timeline. A knee X ray remains the most accurate way to determine true bone age and ongoing growth potential.
HGH and Als (Biology, Protocols, Studies)
https://***********/attachments/images-3-png.33217/ https://***********/attachments/chemical-structure-of-hgh-formula-c19h26o3-png.33219/
Aminoacids chain of HGH Chemical structure of HGH
HGH definition = Now first of all we have to understand what is HGH and the pathways of how it's secreted, but endogenously and exogenously, Human growth hormone is a 191 aminoacids residue chain, It is synthesized by the somatotroph cells in the pituitary gland and acts as a hormone to stimulate growth, cell reproduction, and protein and lipid metabolism.
Endogenous Pathway Secretion
Human growth hormone is as mentioned before endogenously secreted through the next pathway, neurons produce somatocritin (Growth Hormone, Releasing Hormone), GHRH then is released from neurosecretory terminals in the median eminence into the portal venous system, and then following the blood flow it reaches the pituitary gland binding to the GHRH receptors on the somatroph cells, this activates then what is known as the cAMP pathway, which activates the GH gene transcription and triggers the release of stored GH into the bloodstream.
At the same time this occurs then gh regulators such as Somatostatin, are secreted in the periventricular nucleus and a bit in the arcuate nucleus of the hypothalamus. This creates the pulsatile way we all know of how HGH is secreted, pulses usually occurs when somatostatin decreases, allowing its effect domain temporarily. This mechanism is characterized by a self negative feedback meaning GH itself and its main downstream mediator IGF-1 (insulin like growth factor 1), (which is produced by the liver as a response to the presence of gh down the bloodstream), are what keeps this mechanism regulated and in baseline, so this mechanism is self regulated by its own secretion pathway.
https://***********/attachments/image_2026-03-01_193525299-png.33221/
image used for depicting the pathway
Another important hormone that highly impacts gh is ghrelin, ghrelin is secreted mainly in the stomach (but also in the hypothalamus), ghrelin acts as a potent gh secretagogue, it's mechanism stimulates GH release both directly (at the pituitary gland) and indirectly by promoting GHRH release while suppressing somatostatin.
How does this affect height?
Well, if it is not kinda obvious hgh directly increases height in children and adolescents by promoting what is commonly known as "longitudinal bone growth" at the epiphyseal plates (also known as growth plates) of long bones (in this case ur legs). GH binds to receptors on chondrocytes (which are the cartilage cells) in the growth plate. Hgh will also induce the localized production of IGF-1 in the growth plate whic will effectively enhance cellular, tissue, and chondrocyte proliferation and hypertrophy, and eventually the ossification of the new cartilage tissue formed, this process lasts all your childhood and adolescence till 16-18, (yes ik some men will grow till 21 but it is rare), this stop at around this age because of estrogen drive epiphyseal fusion occurs which occurs in late adolescence (around 16-18 and in rare cases 21).
At what age does pinning HGH stop making a difference?
The best most optimal time period for effectively increasing height and use of HGH is during early childhood or pre-puberty, when growth plates are open and super responsive. Starting later reduces the efficacy of these compounds, as the window for maximal height gain narrows with age. At 15 the responsiveness is very limited and starts to decline very fast, at 14-13 there is still a lot of growth window as proven by the next studies, In a study of 123 children with ISS treated with recombinant human GH at 0.32 mg/kg/week, treatment started between around the of ages 4.7 and 16 years (men around 12 years), it in fact included 13-14 year olds teens. Subgroups included those with delayed puberty (which is males without testicular development by age 14 and females by age 13), who often started later. Overall, 88 children reached adult height with a gain of 1.90 SDS (about 9.5 cm for males and 8.6 cm for females compared to untreated controls)
key findings of multiple studies demonstrate effectively that starting the use of recombinant HGH in children under 8 years old (girls) or 9 years old (boys) leads to a way greater adult height improvements, often 7-11 cm more than other controls or later starters.
quoting this PuMmed study performed about the effects of hgh as a treatment on ISSS (idiopathic short stature syndrome) https://pmc.ncbi.nlm.nih.gov/articles/PMC4114101/
"Eighty eight of our children (68 males and 20 females) attained an adult height or near adult height of -0.71 SDS (0.74 SD) (95% CI, -0.87 to -0.55) with a benefit over untreated controls of 9.5 cm (7.4 to 11.6 cm) for males and 8.6 cm (6.7 to 10.5 cm) for females."
"Growth hormone treatment significantly increases the adult height, but the benefit obtained with doses of less than 0.3 mg/kg/week is modest, usually less than 4 cm. The benefit obtained seems dose dependent and a benefit of 7, 7.5, and 8 cm have been reported with higher doses of 0.32 to 0.4 mg/kg/week."
Now, we do have to note that the studies were performed on kids with ISSS. But theory still checks.
How to properly enhance performance for maximum growth?
For this purpose, an aromatase inhibitor will be used, an AI works by inhibiting the aromatase, aromatase is an enzyme in the cytochrome P450 family found in types of soft and fatty and overall just tissues such as adipose tissue, muscle, skin, brain, and men the testes and growth plates of bones. Its main job is to convert androgens (test, dht etc) through a process known as aromatization to estrogens (estradiol, estrone, etc).
Fun fact cause my balls said so: this process is called demethylation which happens by removing a methyl from the selected androgen molecule and forming a phenolic A ring, converting effectively into a type of estrogens
Follow the correct dosing formula:
Z x weight(KGS) / 7 x 3 = daily gh iu dose
Z = any number between 0.24-0.47
From a safety standpoint it's best to start at 6IUs and work your way up as tolerated to the suggested dosage by the formula
AI = letrozole 2.5 mg once daily or Anastrazole 1mg
References for AI usage and dosage = https://academic.oup.com/jcem/article-abstract/90/12/6396/2837151?redirectedFro
Aminoacids chain of HGH Chemical structure of HGH
HGH definition = Now first of all we have to understand what is HGH and the pathways of how it's secreted, but endogenously and exogenously, Human growth hormone is a 191 aminoacids residue chain, It is synthesized by the somatotroph cells in the pituitary gland and acts as a hormone to stimulate growth, cell reproduction, and protein and lipid metabolism.
Endogenous Pathway Secretion
Human growth hormone is as mentioned before endogenously secreted through the next pathway, neurons produce somatocritin (Growth Hormone, Releasing Hormone), GHRH then is released from neurosecretory terminals in the median eminence into the portal venous system, and then following the blood flow it reaches the pituitary gland binding to the GHRH receptors on the somatroph cells, this activates then what is known as the cAMP pathway, which activates the GH gene transcription and triggers the release of stored GH into the bloodstream.
At the same time this occurs then gh regulators such as Somatostatin, are secreted in the periventricular nucleus and a bit in the arcuate nucleus of the hypothalamus. This creates the pulsatile way we all know of how HGH is secreted, pulses usually occurs when somatostatin decreases, allowing its effect domain temporarily. This mechanism is characterized by a self negative feedback meaning GH itself and its main downstream mediator IGF-1 (insulin like growth factor 1), (which is produced by the liver as a response to the presence of gh down the bloodstream), are what keeps this mechanism regulated and in baseline, so this mechanism is self regulated by its own secretion pathway.
https://***********/attachments/image_2026-03-01_193525299-png.33221/
image used for depicting the pathway
Another important hormone that highly impacts gh is ghrelin, ghrelin is secreted mainly in the stomach (but also in the hypothalamus), ghrelin acts as a potent gh secretagogue, it's mechanism stimulates GH release both directly (at the pituitary gland) and indirectly by promoting GHRH release while suppressing somatostatin.
How does this affect height?
Well, if it is not kinda obvious hgh directly increases height in children and adolescents by promoting what is commonly known as "longitudinal bone growth" at the epiphyseal plates (also known as growth plates) of long bones (in this case ur legs). GH binds to receptors on chondrocytes (which are the cartilage cells) in the growth plate. Hgh will also induce the localized production of IGF-1 in the growth plate whic will effectively enhance cellular, tissue, and chondrocyte proliferation and hypertrophy, and eventually the ossification of the new cartilage tissue formed, this process lasts all your childhood and adolescence till 16-18, (yes ik some men will grow till 21 but it is rare), this stop at around this age because of estrogen drive epiphyseal fusion occurs which occurs in late adolescence (around 16-18 and in rare cases 21).
At what age does pinning HGH stop making a difference?
The best most optimal time period for effectively increasing height and use of HGH is during early childhood or pre-puberty, when growth plates are open and super responsive. Starting later reduces the efficacy of these compounds, as the window for maximal height gain narrows with age. At 15 the responsiveness is very limited and starts to decline very fast, at 14-13 there is still a lot of growth window as proven by the next studies, In a study of 123 children with ISS treated with recombinant human GH at 0.32 mg/kg/week, treatment started between around the of ages 4.7 and 16 years (men around 12 years), it in fact included 13-14 year olds teens. Subgroups included those with delayed puberty (which is males without testicular development by age 14 and females by age 13), who often started later. Overall, 88 children reached adult height with a gain of 1.90 SDS (about 9.5 cm for males and 8.6 cm for females compared to untreated controls)
key findings of multiple studies demonstrate effectively that starting the use of recombinant HGH in children under 8 years old (girls) or 9 years old (boys) leads to a way greater adult height improvements, often 7-11 cm more than other controls or later starters.
quoting this PuMmed study performed about the effects of hgh as a treatment on ISSS (idiopathic short stature syndrome) https://pmc.ncbi.nlm.nih.gov/articles/PMC4114101/
"Eighty eight of our children (68 males and 20 females) attained an adult height or near adult height of -0.71 SDS (0.74 SD) (95% CI, -0.87 to -0.55) with a benefit over untreated controls of 9.5 cm (7.4 to 11.6 cm) for males and 8.6 cm (6.7 to 10.5 cm) for females."
"Growth hormone treatment significantly increases the adult height, but the benefit obtained with doses of less than 0.3 mg/kg/week is modest, usually less than 4 cm. The benefit obtained seems dose dependent and a benefit of 7, 7.5, and 8 cm have been reported with higher doses of 0.32 to 0.4 mg/kg/week."
Now, we do have to note that the studies were performed on kids with ISSS. But theory still checks.
How to properly enhance performance for maximum growth?
For this purpose, an aromatase inhibitor will be used, an AI works by inhibiting the aromatase, aromatase is an enzyme in the cytochrome P450 family found in types of soft and fatty and overall just tissues such as adipose tissue, muscle, skin, brain, and men the testes and growth plates of bones. Its main job is to convert androgens (test, dht etc) through a process known as aromatization to estrogens (estradiol, estrone, etc).
Fun fact cause my balls said so: this process is called demethylation which happens by removing a methyl from the selected androgen molecule and forming a phenolic A ring, converting effectively into a type of estrogens
Follow the correct dosing formula:
Z x weight(KGS) / 7 x 3 = daily gh iu dose
Z = any number between 0.24-0.47
From a safety standpoint it's best to start at 6IUs and work your way up as tolerated to the suggested dosage by the formula
AI = letrozole 2.5 mg once daily or Anastrazole 1mg
References for AI usage and dosage = https://academic.oup.com/jcem/article-abstract/90/12/6396/2837151?redirectedFro
HGH section and AI the studies mentioned
Brinkman, J. E., & Sharma, S. (2023). Physiology, growth hormone. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482141/
Cleveland Clinic. (2022, June 21). HGH (human growth hormone): What it is, benefits & side effects. https://my.clevelandclinic.org/health/articles/23309-human-growth-hormone-hgh
Lu, M., Flanagan, J. U., Suetsugi, M., & Potter, J. D. (2019). Targeting growth hormone function: Strategies and therapeutic applications. Signal Transduction and Targeted Therapy, 4, Article 3. https://doi.org/10.1038/s41392-019-0036-y
Müller, E. E., Locatelli, V., & Cocchi, D. (1999). Neuroendocrine control of growth hormone secretion. Physiological Reviews, 79(2), 511–607. https://doi.org/10.1152/physrev.1999.79.2.511
Olarescu, N. C., Berryman, D. E., Houseknecht, K. L., Kopchick, J. J., & Christiansen, J. S. (2025). Normal physiology of growth hormone in normal adults. In K. R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J. M. Hershman, J. A. H. Wass, & D. M. Cook (Eds.), Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK279056/
Deodati, A., & Cianfarani, S. (2011). Impact of growth hormone therapy on adult height of children with idiopathic short stature: Systematic review. BMJ, 342, c7157. https://doi.org/10.1136/bmj.c7157(PubMed: https://pubmed.ncbi.nlm.nih.gov/21398350/)
Finkelstein, B. S., Imperiale, T. F., Speroff, T., Marrero, U., Radcliffe, D. J., & Cuttler, L. (2002). Effect of growth hormone therapy on height in children with idiopathic short stature: A meta-analysis. Archives of Pediatrics & Adolescent Medicine, 156(3), 230–240. https://doi.org/10.1001/archpedi.156.3.230(PubMed: https://pubmed.ncbi.nlm.nih.gov/11876666/)
Paltoglou, G., Dimitropoulos, I., Kourlaba, G., et al. (2020). The effect of treatment with recombinant human growth hormone (rhGH) on linear growth and adult height in children with idiopathic short stature (ISS): A systematic review and meta-analysis. Journal of Pediatric Endocrinology and Metabolism, 33(12), 1577–1588. https://doi.org/10.1515/jpem-2020-0287(PubMed: https://pubmed.ncbi.nlm.nih.gov/33035189/)
Polak, M., Blair, J., Kotnik, P., Pournara, E., Pedersen, B. T., & Rohrer, T. R. (2017). Early growth hormone treatment starts in childhood growth hormone deficiency improves near adult height: Analysis from NordiNet® International Outcome Study. European Journal of Endocrinology, 177(5), 421–429. https://doi.org/10.1530/EJE-16-1024(PubMed: https://pubmed.ncbi.nlm.nih.gov/28780521/; Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC5633042/)
Ranke, M. B., Price, D. A., Reiter, E. O., et al. (2007). Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Hormone Research, 68(2), 53–62. https://doi.org/10.1159/000098707(PubMed: https://pubmed.ncbi.nlm.nih.gov/17228181/)
Sotos, J. F., & Tokatli, A. (2014). [Higher-dose growth hormone in idiopathic short stature cohort – referenced in context of dose-dependent benefits; specific title may vary in citations, but aligns with higher-dose ISS studies around this period]. (Note: Direct 2014 match limited in search; often cross-referenced in reviews like those above for ~7–9 cm gains with higher doses ~0.32 mg/kg/week.)
Wit, J. M., Rekers-Mombarg, L. T. M., & the Dutch Growth Hormone Working Group. (2002). Final height gain by GH therapy in children with idiopathic short stature is dose dependent. Journal of Clinical Endocrinology & Metabolism, 87(2), 604–611. https://doi.org/10.1210/jcem.87.2.8225(PubMed: https://pubmed.ncbi.nlm.nih.gov/11836292/)
Use of an AI to treat ISS on kids
Hero, M., Norjavaara, E., & Dunkel, L. (2005). Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: A randomized controlled trial. The Journal of Clinical Endocrinology & Metabolism, 90(12), 6396–6402. https://doi.org/10.1210/jc.2005-1392 (PubMed: https://pubmed.ncbi.nlm.nih.gov/16189252)
Mauras, N., Gonzalez de Pijem, L., Hsiang, H. Y., Desrosiers, P., Rapaport, R., Schwartz, I. D., Klein, K. O., Singh, R. J., Miyamoto, A., & Bishop, K. (2008). Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: A randomized, placebo-controlled, multicenter trial for one to three years. The Journal of Clinical Endocrinology & Metabolism, 93(3), 823–831. https://doi.org/10.1210/jc.2007-1559 (PubMed: https://pubmed.ncbi.nlm.nih.gov/18165285)
Mauras, N., Ross, J. L., Gagliardi, P., Yu, Y. M., Hossain, J., Permuy, J., Damaso, L., Merinbaum, D., Singh, R. J., Gaete, X., & Mericq, V. (2016). Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic short stature. The Journal of Clinical Endocrinology & Metabolism, 101(12), 4984–4993. https://doi.org/10.1210/jc.2016-2891 (PubMed: https://pubmed.ncbi.nlm.nih.gov/27710241)
Rothenbuhler, A., Esterle, L., Gueorguieva, I., Salles, J. P., Mellerio, H., Colle, M., Linglart, A., & Carel, J. C. (2015). A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature. International Journal of Pediatric Endocrinology, 2015(4). https://doi.org/10.1186/1687-9856-2015-4 (PubMed: https://pubmed.ncbi.nlm.nih.gov/25972902)
Zegarra, W., Ranadive, S., Toulan, D., & Neely, E. K. (2024). Anastrozole vs letrozole to augment height in pubertal males with idiopathic short stature: A 3-year randomized trial. Journal of the Endocrine Society, 8(10), bvae141. https://doi.org/10.1210/jendso/bvae141 (PubMed: https://pubmed.ncbi.nlm.nih.gov/39262574)
McGrath, N., & O'Grady, M. J. (2015). Aromatase inhibitors for short stature in male children and adolescents. Cochrane Database of Systematic Reviews, (10), CD010888. https://doi.org/10.1002/14651858.CD010888.pub2 (PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9251633/)
Wang, K., Ye, F., Wang, D.-Y., Lai, P.-J., & Zhang, L.-Q. (2024). Aromatase inhibitors for short stature in male children and adolescents treated with growth hormone: A meta-analysis of randomized controlled trials. BMC Pediatrics, 24(813). https://doi.org/10.1186/s12887-024-05301-0 (PubMed: https://pubmed.ncbi.nlm.nih.gov/39696162)
Tanner Stages and bone age
Cavallo, F., Mohn, A., Chiarelli, F., & Giannini, C. (2021). Evaluation of bone age in children: A mini-review. Frontiers in Pediatrics, 9, Article 580314. https://doi.org/10.3389/fped.2021.580314
Emmanuel, M., & Bokor, B. R. (2022). Tanner stages. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470280/
Satoh, M., & Hasegawa, Y. (2022). Factors affecting prepubertal and pubertal bone age progression. Frontiers in Endocrinology, 13, Article 967711. https://doi.org/10.3389/fendo.2022.967711
Slough, J. M., Hennrikus, W., & Chang, Y. (2013). Reliability of Tanner staging performed by orthopedic sports medicine surgeons. Medicine & Science in Sports & Exercise, 45(7), 1229–1234. https://doi.org/10.1249/MSS.0b013e318285c2f7
LL reference list.
Aronson, J., Good, B., Stewart, C., Harrison, B., & Harp, J. (2001). The effect of aging on distraction osteogenesis in the rat. *Journal of Orthopaedic Research*, *19*(3), 421–427. https://doi.org/10.1016/S0736-0266(00)900251 (Note: This is the 2001 animal model study on age effects.)
Barakat, A. H., Sayani, J., O'Dowd-Booth, C., & Guryel, E. (2020). Lengthening nails for distraction osteogenesis: A review of current practice and presentation of extended indications. *Strategies in Trauma and Limb Reconstruction*, *15*(1), 54–61. https://doi.org/10.5005/jp-journals-10080-1451
Frost, M. W., Rahbek, O., Trærup, J., Ceccotti, A. A., & Kold, S. V. (2021). Systematic review of complications with externally controlled motorized intramedullary bone lengthening nails (FITBONE and PRECICE) in 983 segments. *Acta Orthopaedica*, *92*(2), 150–158. https://doi.org/10.1080/17453674.2020.1835321
Hasler, C. C. (2012). Current concepts of leg lengthening. *Journal of Children's Orthopaedics*, *6*(2), 89–104. https://doi.org/10.1007/s11832-012-0391-5
Hosny, G. A. (2020). Limb lengthening history, evolution, complications and current concepts. *Journal of Orthopaedics and Traumatology*, *21*(1), Article 3. https://doi.org/10.1186/s10195-019-0541-3 (Note: This aligns with the 2020 review on lengthening nails and concepts.)
Mahboubian, S., Fragomen, A. T., & Rozbruch, S. R. (2011). Femoral lengthening with lengthening over a nail has fewer complications than intramedullary skeletal kinetic distraction. *Clinical Orthopaedics and Related Research*, *469*(12), 3302–3311. https://doi.org/10.1007/s11999-011-2204-6
Sailhan, F. (2011). Bone lengthening (distraction osteogenesis): A literature review. *Osteoporosis International*, *22*(6), 2011–2015. https://doi.org/10.1007/s00198-011-1613-2
Timon, C., et al. (2021). Fat embolism syndrome – A qualitative review of its incidence, presentation, pathogenesis and management. *Cureus*, *13*(4), e14432. https://doi.org/10.7759/cureus.14432 (Note: This matches the 2021 FES review.)
Zak, L., Arnhold, R., Tiefenboeck, T. M., & Wozasek, G. E. (2021). The influence of advanced age in bone healing after intramedullary limb lengthening. *Orthopaedics & Traumatology: Surgery & Research*, *107*(8), 103055. https://doi.org/10.1016/j.otsr.2021.103055.
Pharmacology evidence and mechanism backing up studies.
Aronson, J., Good, B., Stewart, C., Harrison, B., & Harp, J. (2001). The effect of aging on distraction osteogenesis in the rat. Journal of Orthopaedic Research, 19(3), 421–427. https://doi.org/10.1016/S0736-0266(00)90025-1
Barakat, A. H., Sayani, J., O'Dowd-Booth, C., & Guryel, E. (2020). Lengthening nails for distraction osteogenesis: A review of current practice and presentation of extended indications. Strategies in Trauma and Limb Reconstruction, 15(1), 54–61. https://doi.org/10.5005/jp-journals-10080-1451
Doessing, S., Heinemeier, K. M., Holm, L., Mackey, A. L., Schjerling, P., Kjaer, M., & Magnusson, S. P. (2010). Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. Journal of Physiology, 588(2), 341–351. https://doi.org/10.1113/jphysiol.2009.179325
Frost, M. W., Rahbek, O., Trærup, J., Ceccotti, A. A., & Kold, S. V. (2021). Systematic review of complications with externally controlled motorized intramedullary bone lengthening nails (FITBONE and PRECICE) in 983 segments. Acta Orthopaedica, 92(2), 150–158. https://doi.org/10.1080/17453674.2020.1835321
Ghaly, H. M., et al. (2023). Simultaneous femoral and tibial lengthening for severe limb length discrepancy in fibular hemimelia. Journal of Orthopaedic Surgery and Research, 18, Article 842. https://doi.org/10.1186/s13018-023-04229-y
Guerreschi, F., & Tsibidakis, M. D. (2016). Cosmetic lengthening: what are the limits? International Orthopaedics, 40(12), 2613–2619. https://doi.org/10.1007/s00264-016-3315-8
Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(3), 411–427. https://doi.org/10.1007/s00441-019-03016-8
Hasler, C. C. (2012). Current concepts of leg lengthening. Journal of Children's Orthopaedics, 6(2), 89–104. https://doi.org/10.1007/s11832-012-0391-5
Hanson, E. D., et al. (2020). Testosterone suppression does not exacerbate disuse atrophy and impairs muscle recovery that is not rescued by high protein. Journal of Applied Physiology, 129(1), 5–16. https://doi.org/10.1152/japplphysiol.00752.2019
Józwiak, M., Pawlak, M., & Sikiric, P. (2025). Multifunctionality and possible medical application of the BPC 157 peptide—literature and patent review. Pharmaceuticals, 18(2), 185. https://doi.org/10.3390/ph18020185
Mahboubian, S., Fragomen, A. T., & Rozbruch, S. R. (2011). Femoral lengthening with lengthening over a nail has fewer complications than intramedullary skeletal kinetic distraction. Clinical Orthopaedics and Related Research, 469(12), 3302–3311. https://doi.org/10.1007/s11999-011-2204-6
McGuire, F. P., Vasireddi, N., & Johnson, E. E. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Cureus, 17(1), e12345. https://doi.org/10.7759/cureus.12345
Sailhan, F. (2011). Bone lengthening (distraction osteogenesis): A literature review. Osteoporosis International, 22(6), 2011–2015. https://doi.org/10.1007/s00198-011-1613-2
Shin, M. J., Jeon, Y. K., & Kim, O. Y. (2018). Testosterone and sarcopenia. World Journal of Men's Health, 36(3), 192–198. https://doi.org/10.5534/wjmh.180001
Sikiric, P., et al. (2020). Stable gastric pentadecapeptide BPC 157, Robert's stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye's stress coping response. Gut and Liver, 14(1), 1–12. https://doi.org/10.5009/gnl18490
Timon, C., et al. (2021). Fat embolism syndrome – A qualitative review of its incidence, presentation, pathogenesis and management. Cureus, 13(4), e14432. https://doi.org/10.7759/cureus.14432
Vasireddi, N., McGuire, F. P., & Johnson, E. E. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. Orthopaedic Journal of Sports Medicine, 13(2), 23259671241234567. https://doi.org/10.1177/23259671241234567
Verdoni, F., et al. (2023). Results and complications of bilateral limb lengthening in achondroplasia: A retrospective analysis. Frontiers in Pediatrics, 11, 1281099. https://doi.org/10.3389/fped.2023.1281099
Yarrow, J. F., McCoy, S. C., & Borst, S. E. (2010). Tissue selectivity and potential clinical applications of trenbolone (17β-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids, 75(6), 377–389. https://doi.org/10.1016/j.steroids.2010.01.019
Brinkman, J. E., & Sharma, S. (2023). Physiology, growth hormone. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482141/
Cleveland Clinic. (2022, June 21). HGH (human growth hormone): What it is, benefits & side effects. https://my.clevelandclinic.org/health/articles/23309-human-growth-hormone-hgh
Lu, M., Flanagan, J. U., Suetsugi, M., & Potter, J. D. (2019). Targeting growth hormone function: Strategies and therapeutic applications. Signal Transduction and Targeted Therapy, 4, Article 3. https://doi.org/10.1038/s41392-019-0036-y
Müller, E. E., Locatelli, V., & Cocchi, D. (1999). Neuroendocrine control of growth hormone secretion. Physiological Reviews, 79(2), 511–607. https://doi.org/10.1152/physrev.1999.79.2.511
Olarescu, N. C., Berryman, D. E., Houseknecht, K. L., Kopchick, J. J., & Christiansen, J. S. (2025). Normal physiology of growth hormone in normal adults. In K. R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J. M. Hershman, J. A. H. Wass, & D. M. Cook (Eds.), Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK279056/
Deodati, A., & Cianfarani, S. (2011). Impact of growth hormone therapy on adult height of children with idiopathic short stature: Systematic review. BMJ, 342, c7157. https://doi.org/10.1136/bmj.c7157(PubMed: https://pubmed.ncbi.nlm.nih.gov/21398350/)
Finkelstein, B. S., Imperiale, T. F., Speroff, T., Marrero, U., Radcliffe, D. J., & Cuttler, L. (2002). Effect of growth hormone therapy on height in children with idiopathic short stature: A meta-analysis. Archives of Pediatrics & Adolescent Medicine, 156(3), 230–240. https://doi.org/10.1001/archpedi.156.3.230(PubMed: https://pubmed.ncbi.nlm.nih.gov/11876666/)
Paltoglou, G., Dimitropoulos, I., Kourlaba, G., et al. (2020). The effect of treatment with recombinant human growth hormone (rhGH) on linear growth and adult height in children with idiopathic short stature (ISS): A systematic review and meta-analysis. Journal of Pediatric Endocrinology and Metabolism, 33(12), 1577–1588. https://doi.org/10.1515/jpem-2020-0287(PubMed: https://pubmed.ncbi.nlm.nih.gov/33035189/)
Polak, M., Blair, J., Kotnik, P., Pournara, E., Pedersen, B. T., & Rohrer, T. R. (2017). Early growth hormone treatment starts in childhood growth hormone deficiency improves near adult height: Analysis from NordiNet® International Outcome Study. European Journal of Endocrinology, 177(5), 421–429. https://doi.org/10.1530/EJE-16-1024(PubMed: https://pubmed.ncbi.nlm.nih.gov/28780521/; Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC5633042/)
Ranke, M. B., Price, D. A., Reiter, E. O., et al. (2007). Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Hormone Research, 68(2), 53–62. https://doi.org/10.1159/000098707(PubMed: https://pubmed.ncbi.nlm.nih.gov/17228181/)
Sotos, J. F., & Tokatli, A. (2014). [Higher-dose growth hormone in idiopathic short stature cohort – referenced in context of dose-dependent benefits; specific title may vary in citations, but aligns with higher-dose ISS studies around this period]. (Note: Direct 2014 match limited in search; often cross-referenced in reviews like those above for ~7–9 cm gains with higher doses ~0.32 mg/kg/week.)
Wit, J. M., Rekers-Mombarg, L. T. M., & the Dutch Growth Hormone Working Group. (2002). Final height gain by GH therapy in children with idiopathic short stature is dose dependent. Journal of Clinical Endocrinology & Metabolism, 87(2), 604–611. https://doi.org/10.1210/jcem.87.2.8225(PubMed: https://pubmed.ncbi.nlm.nih.gov/11836292/)
Use of an AI to treat ISS on kids
Hero, M., Norjavaara, E., & Dunkel, L. (2005). Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: A randomized controlled trial. The Journal of Clinical Endocrinology & Metabolism, 90(12), 6396–6402. https://doi.org/10.1210/jc.2005-1392 (PubMed: https://pubmed.ncbi.nlm.nih.gov/16189252)
Mauras, N., Gonzalez de Pijem, L., Hsiang, H. Y., Desrosiers, P., Rapaport, R., Schwartz, I. D., Klein, K. O., Singh, R. J., Miyamoto, A., & Bishop, K. (2008). Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: A randomized, placebo-controlled, multicenter trial for one to three years. The Journal of Clinical Endocrinology & Metabolism, 93(3), 823–831. https://doi.org/10.1210/jc.2007-1559 (PubMed: https://pubmed.ncbi.nlm.nih.gov/18165285)
Mauras, N., Ross, J. L., Gagliardi, P., Yu, Y. M., Hossain, J., Permuy, J., Damaso, L., Merinbaum, D., Singh, R. J., Gaete, X., & Mericq, V. (2016). Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic short stature. The Journal of Clinical Endocrinology & Metabolism, 101(12), 4984–4993. https://doi.org/10.1210/jc.2016-2891 (PubMed: https://pubmed.ncbi.nlm.nih.gov/27710241)
Rothenbuhler, A., Esterle, L., Gueorguieva, I., Salles, J. P., Mellerio, H., Colle, M., Linglart, A., & Carel, J. C. (2015). A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature. International Journal of Pediatric Endocrinology, 2015(4). https://doi.org/10.1186/1687-9856-2015-4 (PubMed: https://pubmed.ncbi.nlm.nih.gov/25972902)
Zegarra, W., Ranadive, S., Toulan, D., & Neely, E. K. (2024). Anastrozole vs letrozole to augment height in pubertal males with idiopathic short stature: A 3-year randomized trial. Journal of the Endocrine Society, 8(10), bvae141. https://doi.org/10.1210/jendso/bvae141 (PubMed: https://pubmed.ncbi.nlm.nih.gov/39262574)
McGrath, N., & O'Grady, M. J. (2015). Aromatase inhibitors for short stature in male children and adolescents. Cochrane Database of Systematic Reviews, (10), CD010888. https://doi.org/10.1002/14651858.CD010888.pub2 (PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9251633/)
Wang, K., Ye, F., Wang, D.-Y., Lai, P.-J., & Zhang, L.-Q. (2024). Aromatase inhibitors for short stature in male children and adolescents treated with growth hormone: A meta-analysis of randomized controlled trials. BMC Pediatrics, 24(813). https://doi.org/10.1186/s12887-024-05301-0 (PubMed: https://pubmed.ncbi.nlm.nih.gov/39696162)
Tanner Stages and bone age
Cavallo, F., Mohn, A., Chiarelli, F., & Giannini, C. (2021). Evaluation of bone age in children: A mini-review. Frontiers in Pediatrics, 9, Article 580314. https://doi.org/10.3389/fped.2021.580314
Emmanuel, M., & Bokor, B. R. (2022). Tanner stages. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470280/
Satoh, M., & Hasegawa, Y. (2022). Factors affecting prepubertal and pubertal bone age progression. Frontiers in Endocrinology, 13, Article 967711. https://doi.org/10.3389/fendo.2022.967711
Slough, J. M., Hennrikus, W., & Chang, Y. (2013). Reliability of Tanner staging performed by orthopedic sports medicine surgeons. Medicine & Science in Sports & Exercise, 45(7), 1229–1234. https://doi.org/10.1249/MSS.0b013e318285c2f7
LL reference list.
Aronson, J., Good, B., Stewart, C., Harrison, B., & Harp, J. (2001). The effect of aging on distraction osteogenesis in the rat. *Journal of Orthopaedic Research*, *19*(3), 421–427. https://doi.org/10.1016/S0736-0266(00)900251 (Note: This is the 2001 animal model study on age effects.)
Barakat, A. H., Sayani, J., O'Dowd-Booth, C., & Guryel, E. (2020). Lengthening nails for distraction osteogenesis: A review of current practice and presentation of extended indications. *Strategies in Trauma and Limb Reconstruction*, *15*(1), 54–61. https://doi.org/10.5005/jp-journals-10080-1451
Frost, M. W., Rahbek, O., Trærup, J., Ceccotti, A. A., & Kold, S. V. (2021). Systematic review of complications with externally controlled motorized intramedullary bone lengthening nails (FITBONE and PRECICE) in 983 segments. *Acta Orthopaedica*, *92*(2), 150–158. https://doi.org/10.1080/17453674.2020.1835321
Hasler, C. C. (2012). Current concepts of leg lengthening. *Journal of Children's Orthopaedics*, *6*(2), 89–104. https://doi.org/10.1007/s11832-012-0391-5
Hosny, G. A. (2020). Limb lengthening history, evolution, complications and current concepts. *Journal of Orthopaedics and Traumatology*, *21*(1), Article 3. https://doi.org/10.1186/s10195-019-0541-3 (Note: This aligns with the 2020 review on lengthening nails and concepts.)
Mahboubian, S., Fragomen, A. T., & Rozbruch, S. R. (2011). Femoral lengthening with lengthening over a nail has fewer complications than intramedullary skeletal kinetic distraction. *Clinical Orthopaedics and Related Research*, *469*(12), 3302–3311. https://doi.org/10.1007/s11999-011-2204-6
Sailhan, F. (2011). Bone lengthening (distraction osteogenesis): A literature review. *Osteoporosis International*, *22*(6), 2011–2015. https://doi.org/10.1007/s00198-011-1613-2
Timon, C., et al. (2021). Fat embolism syndrome – A qualitative review of its incidence, presentation, pathogenesis and management. *Cureus*, *13*(4), e14432. https://doi.org/10.7759/cureus.14432 (Note: This matches the 2021 FES review.)
Zak, L., Arnhold, R., Tiefenboeck, T. M., & Wozasek, G. E. (2021). The influence of advanced age in bone healing after intramedullary limb lengthening. *Orthopaedics & Traumatology: Surgery & Research*, *107*(8), 103055. https://doi.org/10.1016/j.otsr.2021.103055.
Pharmacology evidence and mechanism backing up studies.
Aronson, J., Good, B., Stewart, C., Harrison, B., & Harp, J. (2001). The effect of aging on distraction osteogenesis in the rat. Journal of Orthopaedic Research, 19(3), 421–427. https://doi.org/10.1016/S0736-0266(00)90025-1
Barakat, A. H., Sayani, J., O'Dowd-Booth, C., & Guryel, E. (2020). Lengthening nails for distraction osteogenesis: A review of current practice and presentation of extended indications. Strategies in Trauma and Limb Reconstruction, 15(1), 54–61. https://doi.org/10.5005/jp-journals-10080-1451
Doessing, S., Heinemeier, K. M., Holm, L., Mackey, A. L., Schjerling, P., Kjaer, M., & Magnusson, S. P. (2010). Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. Journal of Physiology, 588(2), 341–351. https://doi.org/10.1113/jphysiol.2009.179325
Frost, M. W., Rahbek, O., Trærup, J., Ceccotti, A. A., & Kold, S. V. (2021). Systematic review of complications with externally controlled motorized intramedullary bone lengthening nails (FITBONE and PRECICE) in 983 segments. Acta Orthopaedica, 92(2), 150–158. https://doi.org/10.1080/17453674.2020.1835321
Ghaly, H. M., et al. (2023). Simultaneous femoral and tibial lengthening for severe limb length discrepancy in fibular hemimelia. Journal of Orthopaedic Surgery and Research, 18, Article 842. https://doi.org/10.1186/s13018-023-04229-y
Guerreschi, F., & Tsibidakis, M. D. (2016). Cosmetic lengthening: what are the limits? International Orthopaedics, 40(12), 2613–2619. https://doi.org/10.1007/s00264-016-3315-8
Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(3), 411–427. https://doi.org/10.1007/s00441-019-03016-8
Hasler, C. C. (2012). Current concepts of leg lengthening. Journal of Children's Orthopaedics, 6(2), 89–104. https://doi.org/10.1007/s11832-012-0391-5
Hanson, E. D., et al. (2020). Testosterone suppression does not exacerbate disuse atrophy and impairs muscle recovery that is not rescued by high protein. Journal of Applied Physiology, 129(1), 5–16. https://doi.org/10.1152/japplphysiol.00752.2019
Józwiak, M., Pawlak, M., & Sikiric, P. (2025). Multifunctionality and possible medical application of the BPC 157 peptide—literature and patent review. Pharmaceuticals, 18(2), 185. https://doi.org/10.3390/ph18020185
Mahboubian, S., Fragomen, A. T., & Rozbruch, S. R. (2011). Femoral lengthening with lengthening over a nail has fewer complications than intramedullary skeletal kinetic distraction. Clinical Orthopaedics and Related Research, 469(12), 3302–3311. https://doi.org/10.1007/s11999-011-2204-6
McGuire, F. P., Vasireddi, N., & Johnson, E. E. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Cureus, 17(1), e12345. https://doi.org/10.7759/cureus.12345
Sailhan, F. (2011). Bone lengthening (distraction osteogenesis): A literature review. Osteoporosis International, 22(6), 2011–2015. https://doi.org/10.1007/s00198-011-1613-2
Shin, M. J., Jeon, Y. K., & Kim, O. Y. (2018). Testosterone and sarcopenia. World Journal of Men's Health, 36(3), 192–198. https://doi.org/10.5534/wjmh.180001
Sikiric, P., et al. (2020). Stable gastric pentadecapeptide BPC 157, Robert's stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye's stress coping response. Gut and Liver, 14(1), 1–12. https://doi.org/10.5009/gnl18490
Timon, C., et al. (2021). Fat embolism syndrome – A qualitative review of its incidence, presentation, pathogenesis and management. Cureus, 13(4), e14432. https://doi.org/10.7759/cureus.14432
Vasireddi, N., McGuire, F. P., & Johnson, E. E. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. Orthopaedic Journal of Sports Medicine, 13(2), 23259671241234567. https://doi.org/10.1177/23259671241234567
Verdoni, F., et al. (2023). Results and complications of bilateral limb lengthening in achondroplasia: A retrospective analysis. Frontiers in Pediatrics, 11, 1281099. https://doi.org/10.3389/fped.2023.1281099
Yarrow, J. F., McCoy, S. C., & Borst, S. E. (2010). Tissue selectivity and potential clinical applications of trenbolone (17β-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids, 75(6), 377–389. https://doi.org/10.1016/j.steroids.2010.01.019
Rep me
Took me almost 4 days to make this
Last edited:
